Literature DB >> 10389918

High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.

C H Takimoto1, L K Yee, D J Venzon, B Schuler, F Grollman, C Chabuk, J M Hamilton, A P Chen, C J Allegra, J L Grem.   

Abstract

The purpose of the study was to examine inter- and intrapatient variation in 5-fluorouracil (5-FU) plasma concentrations in adult cancer patients receiving a 3-day drug infusion. Fourteen patients received 1266 mg/m2 N-(phosphonacetyl)-L-aspartate (PALA) infused i.v. over 15 min on day 1, followed immediately by a loading dose of 500 mg/m2 calcium leucovorin over 30 min. Then a prolonged infusion of leucovorin at 500 mg/m2/day and 5-FU at 1750 mg/m2/day was administered as either a constant rate or as a circadian infusion over 72 h. During constant rate infusions, 5-FU concentrations within individuals varied by 1.7-fold, but no uniform time of peak or trough concentration was observed. Transformation of these data by setting the time of peak to 0 h and by expressing concentrations as the percentage of the 24-h mean value revealed a nonrandom distribution of the time from peak to trough with a median time of 12 h (P = 0.027). These transformed data were also successfully fit to a circadian cosinor function (P < 0.001). During multiple constant rate 5-FU infusions, the intrapatient variability was high; the times of peak 5-FU concentration occurred at the same approximate sampling time 43% of the time, and troughs coincided 17% of the time. No difference in clinical toxicity was observed when matched constant rate and circadian infusions of 5-FU were compared. High inter- and intrapatient variability exists in 5-FU plasma concentrations in adult cancer patients during constant rate infusions with no evidence of a consistent circadian rhythm in untransformed data.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389918

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  14 in total

Review 1.  Pharmacology of fluorinated pyrimidines: eniluracil.

Authors:  S D Baker
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 2.  Capecitabine.

Authors:  D R Budman
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 3.  5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.

Authors:  J L Grem
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

4.  Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.

Authors:  Jiří Grim; Miloš Hroch; Hroch Miloš; Jaroslav Chládek; Chládek Jaroslav; Jiří Petera; Petera Jiří; Jiřina Martínková; Martínková Jiřina
Journal:  Clin Pharmacokinet       Date:  2015-05       Impact factor: 6.447

5.  Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse.

Authors:  Ofonime Udofot; Kevin Affram; Taylor Smith; Bulumko Tshabe; Sunil Krishnan; Mandip Sachdeva; Edward Agyare
Journal:  J Nat Sci       Date:  2016

6.  Oral microbiota reduce wound healing capacity of epithelial monolayers, irrespective of the presence of 5-fluorouracil.

Authors:  Eline Vanlancker; Barbara Vanhoecke; Tom Sieprath; Janie Bourgeois; Annelore Beterams; Barbara De Moerloose; Winnok H De Vos; Tom Van de Wiele
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-16

7.  Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.

Authors:  Michael Michael; Peter Gibbs; Robert Smith; Alex Godwood; Stuart Oliver; Niall Tebbutt
Journal:  Invest New Drugs       Date:  2008-11-11       Impact factor: 3.850

Review 8.  Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.

Authors:  Nirmala Tilija Pun; Chul-Ho Jeong
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-16

9.  A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.

Authors:  L-B Weiswald; S Richon; G Massonnet; J-M Guinebretière; S Vacher; I Laurendeau; P Cottu; E Marangoni; F Nemati; P Validire; D Bellet; I Bièche; V Dangles-Marie
Journal:  Br J Cancer       Date:  2013-03-28       Impact factor: 7.640

10.  Local treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaT.

Authors:  J Hartinger; P Veselý; E Matoušková; S Argalacsová; L Petruželka; I Netíková
Journal:  ScientificWorldJournal       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.